CA2965189C - A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens - Google Patents

A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens Download PDF

Info

Publication number
CA2965189C
CA2965189C CA2965189A CA2965189A CA2965189C CA 2965189 C CA2965189 C CA 2965189C CA 2965189 A CA2965189 A CA 2965189A CA 2965189 A CA2965189 A CA 2965189A CA 2965189 C CA2965189 C CA 2965189C
Authority
CA
Canada
Prior art keywords
pbc
kelch
autoantibody
elisa
autoantibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2965189A
Other languages
English (en)
French (fr)
Other versions
CA2965189A1 (en
Inventor
Mark J. Lim
Heather P. Ostendorff
Kenneth J. Rothschild
Donald B. Bloch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Ambergen Inc
Original Assignee
General Hospital Corp
Ambergen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43857083&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2965189(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by General Hospital Corp, Ambergen Inc filed Critical General Hospital Corp
Publication of CA2965189A1 publication Critical patent/CA2965189A1/en
Application granted granted Critical
Publication of CA2965189C publication Critical patent/CA2965189C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2965189A 2009-10-05 2010-10-05 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens Active CA2965189C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24876809P 2009-10-05 2009-10-05
US61/248768 2009-10-05
CA2776688A CA2776688C (en) 2009-10-05 2010-10-05 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2776688A Division CA2776688C (en) 2009-10-05 2010-10-05 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens

Publications (2)

Publication Number Publication Date
CA2965189A1 CA2965189A1 (en) 2011-04-14
CA2965189C true CA2965189C (en) 2020-06-30

Family

ID=43857083

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2776688A Active CA2776688C (en) 2009-10-05 2010-10-05 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
CA2965189A Active CA2965189C (en) 2009-10-05 2010-10-05 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2776688A Active CA2776688C (en) 2009-10-05 2010-10-05 A method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens

Country Status (7)

Country Link
US (4) US8852956B2 (enExample)
EP (2) EP2486407B1 (enExample)
JP (2) JP5710623B2 (enExample)
AU (2) AU2010303628B2 (enExample)
CA (2) CA2776688C (enExample)
ES (2) ES2566762T3 (enExample)
WO (1) WO2011044125A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2566762T3 (es) * 2009-10-05 2016-04-15 Ambergen Inc. Un procedimiento de diagnóstico de cirrosis biliar primaria (PBC) usando nuevos autoantígenos
CN102627695B (zh) * 2012-03-23 2014-10-22 中国医学科学院北京协和医院 原发性胆汁性肝硬化特异性自身抗原及其应用
CN104292323B (zh) * 2012-03-23 2017-04-05 中国医学科学院北京协和医院 原发性胆汁性肝硬化特异性自身抗原及其应用
CN104292322A (zh) * 2012-03-23 2015-01-21 中国医学科学院北京协和医院 原发性胆汁性肝硬化特异性自身抗原及其应用
WO2020190700A1 (en) * 2019-03-15 2020-09-24 Chan Zuckerberg Biohub, Inc. Autoantibodies as biomarker of paraneoplastic encephalitis associated with testicular cancer
WO2022150536A1 (en) * 2021-01-08 2022-07-14 Inova Diagnostics, Inc. Compositions and methods for diagnosing primary biliary cirrhosis
CN113009148A (zh) * 2021-02-10 2021-06-22 中国医学科学院北京协和医院 用于诊断抗sp100抗体阳性与阴性pbc患者的糖链标志物及其用途

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4208479A (en) * 1977-07-14 1980-06-17 Syva Company Label modified immunoassays
CA1341231C (en) * 1986-12-16 2001-05-15 Ross Leon Coppel Primary biliary cirrhosis autoantigen
JPH03291568A (ja) * 1990-04-09 1991-12-20 Igaku Seibutsugaku Kenkyusho:Kk 抗ミトコンドリアｍ↓２抗体の検出用試薬及び測定法
JP3472048B2 (ja) * 1995-10-09 2003-12-02 鐘淵化学工業株式会社 自己免疫疾患の診断薬
US6111071A (en) * 1996-06-24 2000-08-29 The Regents Of The University Of California Recombinant fusion protein comprising PDC-E2, BCOADC-E2 and OGDC-E2 and uses thereof
JPH1138008A (ja) * 1997-07-16 1999-02-12 Sumitomo Electric Ind Ltd 自己抗体の検出方法および検出試薬
WO2002008383A2 (en) * 2000-07-24 2002-01-31 The General Hospital Corporation Sp110, a polypeptide component of the nuclear body
AU2002254431A1 (en) * 2001-03-27 2002-10-08 M. Eric Gershwin Antibodies against autoantigens of primary biliary cirrhosis and methods of making and using them
AU2005209256B2 (en) * 2004-01-21 2010-11-18 Gilead Sciences, Inc. Use of adefovir or tenofovir for inhibiting MMTV-like viruses involved in breast cancer and primary biliary cirrhosis
JP2006071409A (ja) * 2004-09-01 2006-03-16 Kansai Tlo Kk シェーグレン症候群診断キット
WO2007043103A1 (ja) * 2005-09-30 2007-04-19 Kansai Technology Licensing Organization Co., Ltd. シェーグレン症候群診断法及び診断キット
JP2007245505A (ja) 2006-03-15 2007-09-27 Fujifilm Corp 平版印刷版原版、平版印刷版およびその作製方法
US20090047689A1 (en) * 2007-06-20 2009-02-19 John Kolman Autoantigen biomarkers for early diagnosis of lung adenocarcinoma
JP5471724B2 (ja) 2009-09-30 2014-04-16 大日本印刷株式会社 化粧シート
ES2566762T3 (es) * 2009-10-05 2016-04-15 Ambergen Inc. Un procedimiento de diagnóstico de cirrosis biliar primaria (PBC) usando nuevos autoantígenos
JP2012206482A (ja) 2011-03-30 2012-10-25 Daikyonishikawa Corp 樹脂成形品の組付け構造

Also Published As

Publication number Publication date
EP3012631A1 (en) 2016-04-27
US20240159749A1 (en) 2024-05-16
CA2965189A1 (en) 2011-04-14
JP6012794B2 (ja) 2016-10-25
WO2011044125A8 (en) 2012-09-13
EP2486407B1 (en) 2016-02-10
ES2566762T3 (es) 2016-04-15
CA2776688A1 (en) 2011-04-14
EP2486407A1 (en) 2012-08-15
EP3012631B1 (en) 2018-05-23
US11885802B2 (en) 2024-01-30
AU2015238816B2 (en) 2017-10-05
EP2486407A4 (en) 2013-04-10
WO2011044125A1 (en) 2011-04-14
AU2010303628A1 (en) 2012-04-12
JP2015143695A (ja) 2015-08-06
ES2681839T3 (es) 2018-09-17
US20120244562A1 (en) 2012-09-27
US8852956B2 (en) 2014-10-07
AU2015238816A1 (en) 2015-10-29
US20150057170A1 (en) 2015-02-26
US20170307607A1 (en) 2017-10-26
AU2010303628B2 (en) 2015-07-09
CA2776688C (en) 2017-06-20
JP5710623B2 (ja) 2015-04-30
JP2013506837A (ja) 2013-02-28

Similar Documents

Publication Publication Date Title
US20240159749A1 (en) Method for diagnosing primary biliary cirrhosis (pbc) using novel autoantigens
US11199549B2 (en) MEl'hods and means for diagnosing spondylarthritis using autoantibody markers
Amlani et al. Anti-NT5c1A autoantibodies as biomarkers in inclusion body myositis
US11609237B2 (en) Marker sequences for diagnosing and stratifying systemic sclerosis patients
CN110716050A (zh) 抗原组合在制备用于肺癌相关自身抗体检测的试剂盒中的用途以及相应的试剂盒和检测方法
US11719694B2 (en) Biomarkers in autoimmune liver disease
CN104292322A (zh) 原发性胆汁性肝硬化特异性自身抗原及其应用
US20210333275A1 (en) Pan-isotype immunoglobulin fingerprinting
US9915662B2 (en) Protein microarray for characterizing the specificity of the monoclonal immunoglobulins of MGUS or myeloma patients
JP5605375B2 (ja) Ｋｕ８６に対する自己抗体の免疫測定方法、それに用いるキット、及びそれを用いた原発性肝細胞癌の判定方法
CN102627695B (zh) 原发性胆汁性肝硬化特异性自身抗原及其应用
CN104292323B (zh) 原发性胆汁性肝硬化特异性自身抗原及其应用
CN113817025A (zh) Sle抗原表位多肽在鉴别sle和其他自身免疫疾病中的作用
CN113831401A (zh) 一种sle抗原表位多肽及其在sle诊断中的作用

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170426